A series of 34 1,2,3-triazole-naphthoquinone conjugates were synthesized via copper-catalyzed cycloaddition (CuAAC). They were evaluated for their in vitro antimalarial activity against chloroquine-sensitive strains of Plasmodium falciparum and against three different tumor cell lines (SKBr-3, MCF-7, HEL). The most active antimalarial compounds showed a low antiproliferative activity. Simplified analogues were also obtained and some structure-activity relationships were outlined. The best activity was obtained by compounds 3s and 3j, having IC 50 of 0.8 and 1.2 µM, respectively. Molecular dockings were also carried on Plasmodium falciparum enzyme dihydroorotate dehydrogenase (Pf DHODH) in order to rationalize the results.
Introduction
Malaria, a disease caused by parasites of the Plasmodium genus and spread through the bites of infected mosquitoes, was responsible for an estimated 219 million clinical cases and 435,000 deaths worldwide in 2017, mostly among children under the age of five [1] . Most of the malarial infections and deaths are due to Plasmodium falciparum and Plasmodium vivax species. Available therapeutic agents are already limited in their efficacy, and drug resistance threatens to diminish the ability to treat and prevent the disease further. Despite a renewed effort to identify antimalarial compounds, the drug discovery lacks target diversity and most malaria drugs are only efficacious during the asexual blood stage of parasite infection [2] . Thus, it is necessary the search for new antimalarial drugs that overcome the resistance and act through new mechanisms.
Natural products have played a pivotal role in the discovery of lead compounds for the treatment of malaria, from quinine and artemisinin to ozonide-based compounds. Many of these natural products have served as a starting point for the development and design of antimalarial drugs currently in the clinic or in the development phase [3] .
1,4-Naphthoquinones are a class of compounds broadly studied in natural products chemistry and medicinal chemistry [4] [5] [6] . Within these studies, the antimalarial activity has been reported for several 1,4-Naphthoquinones are a class of compounds broadly studied in natural products chemistry and medicinal chemistry [4] [5] [6] . Within these studies, the antimalarial activity has been reported for several 1,4-naphthoquinones [7] [8] [9] [10] [11] [12] [13] [14] . The antiparasitic activity of the quinones is related to several mechanisms such as enzymatic inhibition (e.g., dihydroorotate dehydrogenase, glutathione reductase, and glycerol glyceraldehyde-3-phosphate dehydrogenase), alkylation of biomolecules, competitive inhibition of the cytochrome bc1 complex, depletion of glutathione, and generation of reactive oxygen species, among others [15] . Lawsone derivatives containing the 2-hydroxy-1,4-naphthoquinone scaffold have been highly explored for the development of novel antiparasitics [7, [16] [17] [18] [19] . Atovaquone, buparvaquone, and parvaquone and are 3-substituted-2-hydroxy-1,4-naphthoquinones used as antipneumocystic (buparvaquone and parvaquone) and antimalarial (atovaquone) agents, which exemplifies the potentiality of such scaffold in the development of novel drugs [3] . Additionally, some studies indicate the potential application of natural or synthetic 2-amino-1,4-naphthoquinones and 2-amino-1,2-naphthoquinones as antiplasmodial agents [20] .
Nowadays, molecular hybridization has emerged as a promising tool for the drug design process and medicinal chemistry. In this strategy, two or more different pharmacophoric units are covalently linked into a single hybrid molecule with best properties as compared to the parent drugs [20] . Molecular hybridization [21] is beneficial, as different targets are activated by a single molecule, and is particularly interesting where treatment is limited to a few commercial drugs or in cases where the bioactive compounds present pharmacokinetic and pharmacodynamic limitations or high toxicity.
Guided by the concept of molecular hybridization, some triazole naphthoquinones have been prepared as trypanocidal agents. Thus, da Silva Júnior et al. synthesized diverse α-lapachone-triazoles (I) [22] , nor-α-lapachone-triazoles (II) [22, 23] , β-lapachone-triazoles (III) [24] , nor-β-lapachone-triazoles (IV) [25, 26] , and 1,4-naphthoquinone coupled 1,2,3-triazoles (V) [25] ( Figure 1) , some of them resulted in being potent compounds against antimony-sensitive and -resistant leishmania. In the present work a new series of naphthoquinonolyl triazole derivatives have been synthesized from lawsone (2-hydroxy-1,4-naphthoquinone) and evaluated for their in vitro activity In the present work a new series of naphthoquinonolyl triazole derivatives have been synthesized from lawsone (2-hydroxy-1,4-naphthoquinone) and evaluated for their in vitro activity against chloroquine-sensitive strains of Plasmodium falciparum and for antiproliferative activity against some tumor cell lines. From the obtained results some structure-activity relationships were outlined. Furthermore, docking studies on the Plasmodium falciparum enzyme dihydroorotate dehydrogenase (Pf DHODH) suggested that these compounds could act as inhibitors of this enzyme. 
Results and Discussion
The 1,2,3-triazole-naphthoquinone derivatives (3) were synthesized using a copper(I)-catalyzed Huisgen 1,3-dipolar cycloaddition reaction [28] of the corresponding O-propargylated naphthoquinone (1) with alkyl or aryl azides (2) (Table 1) . Table 1 . Synthesis and structure of 1,2,3-triazole-naphthoquinones (3a-3u).
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The 1,2,3-triazole-naphthoquinone derivatives (3) were synthesized using a copper(I)-catalyzed Huisgen 1,3-dipolar cycloaddition reaction [28] of the corresponding O-propargylated naphthoquinone (1) with alkyl or aryl azides (2) ( Table 1) . dehydrogenase (PfDHODH) suggested that these compounds could act as inhibitors of this enzyme.
The 1,2,3-triazole-naphthoquinone derivatives (3) were synthesized using a copper(I)-catalyzed Huisgen 1,3-dipolar cycloaddition reaction [28] of the corresponding O-propargylated naphthoquinone (1) with alkyl or aryl azides (2) ( Table 1) . The starting O-propargyl-naphthoquinone was prepared in good yields by reaction of 2-hydroxy-1,4-naphthoquinone and propargyl bromide using K 2 CO 3 in dimethylformamide. The aryl and alkyl azides were obtained from alkyl bromide or boronic acids and sodium azide [29] . Table 1 shows the structures and yields of a variety of substituted 1,2,3-triazole-1,4-naphtho quinone conjugates. As we can see, moderate-to-good yields were obtained. The structures of compounds (3a-3u) were characterized by 1 H-NMR, 13 C-NMR, and HRMS. In the 1 H-NMR, the triazolic hydrogen appeared as a singlet at δ 8-10 ppm, the naphthoquinone hydrogen and the methylene hydrogens were also observed as singlets at δ 6.3-6.7 ppm and δ 5.1-5.5 ppm, respectively. Conjugates with aliphatic substituents on the triazol moiety were prepared (3a-3c, 3f, 3o). Some derivatives containing different electron donating and withdrawing groups linked to the phenyl group of the triazole ring were also obtained (3j-3s). Finally, diverse hybrid compounds were prepared using the triazole ring as a linker between the naphthoquinone nucleus and diverse privileged structures such as coumarin (3g), 1,8-naphthalimide (3h-3i), 1,4-naphthoquinone (3d-3e), and indol (3t).
The obtained 1,2,3-triazole-naphthoquinone derivatives (3a-3u) were evaluated in vitro against F-32 Tanzania (chloroquine sensitive) strains of Plasmodium falciparum. These compounds were also tested against SKBr-3 (human breast cancer), MCF-7 (human breast adenocarcinoma), and HEL (human erythroleukemia) tumor cell lines. The results obtained are shown in Table 2 .
From the obtained results some structure-activity relationships were outlined. Regarding the antiplasmodial activity, 16 compounds of the 21 were active with IC 50 values ranging from 17.9 to 0.8 µM. The introduction of indol (3t), coumarin (3g), N-substituted-naphthalimide (3h), and 2-amine-1,4-naphthoquinone (3e) on the 1,2,3-triazole ring led to inactive compounds, whereas the N-unsubstituted naphthalimide (3d) and the 1,4-naphthoquinone (3d) had IC 50 values of 5.5 ± 0.1 and 1.9 ± 0.09 µM, respectively. The conjugate derivatives with alkyl chains (3a-3b) and benzyl group (3c) on the triazole ring showed worse activities than those with an attached aryl group. In the aryl series (3j-3s), similar antiplasmodial activity was observed with electron-donating (3k, 3l, 3o) or electron-withdrawing substituents in the aromatic ring. In fact, the best IC 50 values were achieved by compound 3s (0.8 ± 0.1 µM) bearing a methoxy at C-4 and a fluor group at C-3 and 3j (1.2 ± 0.2 µM) with an unsubstituted phenyl ring. The presence of hydrogen bond donors such as -CH 2 OH (3p) or -SH (3q) produced inactivity. The introduction of conjugated systems such as [1,1 -biphenyl]-4-carbonyl (3f) or 1-(trifluoromethyl)-4-vinylbenzene (3u) led to good values of IC 50 (1.6 ± 0.1 and 3.3 ± 0.07 µM, respectively). 17.9 ± 2.5 >10 >10 5.9 ± 0.7 3d
1.9 ± 0.09
Concerning the antiproliferative activity most part of the compounds showed IC 50 > 10 µM against the three tumor cell lines assayed. Only compounds 3a, 3c, 3h, 3i, 3p, and 3r presented Molecules 2019, 24, 3917 5 of 22 moderate antiproliferative activity against HEL (human erythroleukemia) with IC 50 values ranging from 3.8 to 7.3 µM. These results are interesting from a selective index point of view, as the most active antiplasmodial compounds (3d, 3f, 3j, 3l, 3m and 3s) present a low antiproliferative activity.
In order to deepen the structural determinants responsible of the antiplasmodial activity, we decided to prepare several derivatives. Thus, we wanted to evaluate the influence in the activity of the -CH 2 O-linker, and two compounds (4a and 4j) were synthesized with the triazol ring attached at carbon C-2 of the naphthoquinone nucleus (Scheme 1).
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Scheme 1. Synthesis of compounds 4a and 4j.
When 4a and 4j were assayed, a loss of activity (IC50 > 10 μg/mL) with respect to the active compounds 3a and 3j, having the -OCH2-linker, was detected. Next, we analysed the antiplasmodial activity of the 2-hydroxy-1,4-naphthoquinone (lawsone) and some (4-aryl-1H-1,2,3-triazol-1-yl) methanol derivatives (Figure 2 and Supplementary Material) as simplified fragments of the active structures. All of them were inactive (IC50 > 10 μg/mL), which indicated the importance for the biological activity of both the quinone ring and the substituted triazole. Next, we evaluated the influence on the activity of an isosteric modification by replacing the -OCH2linker by -NHCH2-. Thus, the following conjugates were prepared from N-propargylated-1,4-naphthoquinone and alkyl and aryl azides in higher yields than those from O-propargylated-1,4-naphthoquinone ( Table 3 ). None of the N-derivatives resulted active (IC50 > 10 Scheme 1. Synthesis of compounds 4a and 4j.
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When 4a and 4j were assayed, a loss of activity (IC50 > 10 μg/mL) with respect to the active compounds 3a and 3j, having the -OCH2-linker, was detected. Next, we analysed the antiplasmodial activity of the 2-hydroxy-1,4-naphthoquinone (lawsone) and some (4-aryl-1H-1,2,3-triazol-1-yl) methanol derivatives (Figure 2 and Supplementary Material) as simplified fragments of the active structures. All of them were inactive (IC50 > 10 μg/mL), which indicated the importance for the biological activity of both the quinone ring and the substituted triazole. Next, we evaluated the influence on the activity of an isosteric modification by replacing the -OCH2linker by -NHCH2-. Thus, the following conjugates were prepared from N-propargylated-1,4-naphthoquinone and alkyl and aryl azides in higher yields than those from O-propargylated-1,4-naphthoquinone ( Table 3 ). None of the N-derivatives resulted active (IC50 > 10 Next, we evaluated the influence on the activity of an isosteric modification by replacing the -OCH 2 -linker by -NHCH 2 -. Thus, the following conjugates were prepared from N-propargylated-1,4-naphthoquinone and alkyl and aryl azides in higher yields than those from O-propargylated-1,4-naphthoquinone ( Table 3 ). None of the N-derivatives resulted active (IC 50 > 10 µg/mL), which indicated that the replacing of an acceptor of hydrogen bonds by donor hydrogen bonds in this part of the molecule led to a drastic loss of activity.
In order to rationalize all these results, we carried out molecular dockings on the enzyme dihydroorotate dehydrogenase (DHODH). Dihydroorotate dehydrogenase (DHODH) is an enzyme essential to the fourth and rate limiting step in de novo pyrimidine biosynthesis, and it catalyzes the conversion of dihydroorotate (DHO) to orotate (ORO) with the reduction of ubiquinone. The significance of pyrimidine bases for cell proliferation and metabolism determines human DHODH as an attractive target for the development of new drug candidates in different clinical applications for arthritis, malaria, and cancer [30, 31] . Table 3 . Preparation of isosteric analogues of 1,2,3-triazole-naphthoquinones (7b-7d, 7h, 7j-7o, 7r-7t).
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An analysis of the docking results clearly indicated that one of the most active compounds in this study, 3j, showed substantial binding affinities, a good steric and electronic complementarity, and fits well into the Pf DHODH binding site. In addition, these docking results strongly suggested that the compound 3j and the inhibitor bounded in the putative quinone-binding tunnel shared a common binding mode. The best docking score was −6.70 kcal mol −1 . According to the predicted binding modes, the compound 3j showed a π-π stacking interaction between the triazol ring present in these compounds with the amino acid residue Phe 188 (Figure 3 ).
probable binding mode and to propose a mode of action of the antiplasmodial activity of synthesized 1,2,3-triazole-naphthoquinone conjugates, a molecular docking study was performed on reported crystal structure of Plasmodium falciparum enzyme dihydroorotate dehydrogenase using the Glide software [36] . The X-ray crystal structure of PfDHODH (Protein Data Bank (PDB) 1TV5) [37] was retrieved from the Protein Data Bank having a resolution of 2.4 Å, which has been reported to be used frequently for docking studies [38] . Hence, we docked all the 1,2,3-triazole-naphthoquinone conjugates into the putative quinone-binding tunnel formed by the N-terminal domain to see if these compounds could interact with this target and, consequently, to understand the possible key active site interactions. An analysis of the docking results clearly indicated that one of the most active compounds in this study, 3j, showed substantial binding affinities, a good steric and electronic complementarity, and fits well into the PfDHODH binding site. In addition, these docking results strongly suggested that the compound 3j and the inhibitor bounded in the putative quinone-binding tunnel shared a common binding mode. The best docking score was −6.70 kcal mol −1 . According to the predicted In addition, three hydrogen bonds were detected, two of them between Arg 265 and Tyr 528 with the carbonyl groups belonging to the quinone moiety and another hydrogen bond between His 185 and the ether group that link the quinone moity and the triazole ring. Moreover, in the favored docking conformation, many hydrophobic side chain residues of the putative quinone-binding tunnel were in close proximity to naphthoquinone-triazole conjugates. In the predicted pose of the compound 3j, the potential hydrophobic interactions involve residues such as Cys 175, Cys 184, Phe 227, Leu 172, Met 536, and Phe 171. The presence of polar contacts with a considerable number of residues, as well as hydrophobic interactions, seem to play a fundamental role in the binding of these compounds, which could explain their antiplasmodial activity.
Finally, some physicochemical descriptors (MW, LogP, H-bond donors, H-bond acceptors, rotable bonds, and TPSA) for the best active compounds were calculated using Molinspiration Cheminformatics software (2019) and the corresponding values are included in Table 4 . As we can observe, all of them showed values within the accepted ranges for drug-like molecules. descriptors of 3d, 3f, 3j, 3l, 3m, and 3s 
Materials and Methods

General Methods
The reactions under microwave irradiation were performed in a Biotage Initiator 2.5 using standard sealed microwave glass vials (2-5 mL) and a normal absorption level. Solvents were dried immediately prior to use by distillation from a drying agent: Tetrahydrofuran (THF) from Na/benzophenone and CH 3 CN from CaH 2 [39] . Commercial reagents were purchased from Sigma-Aldrich Chemical Co. and Alfa Aesar and were used without further purification. Analytical thin-layer chromatography was performed on Polygram SIL G/UV254 silica gel plates and chromatograms were visualized under UV light (254 and 360 nm). Purification on column chromatography was carried out on Merck silica gel 60 (0.063-0.2 mm) with the indicated solvent mixtures. Pre-coated TLC plates SIL G-100 UV254 (Macherey-Nagel) and SILICA GEL GF plates (1000 µm, Analtech) were used for preparative TLC purification. 1 H and 13 C-NMR spectra were acquired in CDCl 3 (0.03% v/v TMS), DMSO-d 6 or CD 3 CN at room temperature using Bruker Avance instruments (500 or 600 MHz for 1 H-NMR and 125 or 150 MHz for 13 C-NMR). Chemical shifts were reported in parts per million (ppm) from tetramethylsilane and referenced to the residual solvent peak (CDCl 3 : δ 7.26 for 1 H-NMR, δ 77.00/77.16 for 13 C-NMR; DMSO-d 6 : δ 2.50 for 1 H-NMR, δ 39.52 for 13 C-NMR; CD 3 CN: δ 1.93 for 1 H-NMR, δ 1.32, 118.26 for 13 C-NMR). For 1 H-NMR, data were reported in the following manner: chemical shift (integration, multiplicity, coupling constant where applicable). The following abbreviations were used: s (singlet), br (broad), d (doublet), t (triplet), dd (double doublet), td (triplet of doublets), m (multiplet). Coupling constants (J) were given in Hertz (Hz) . 13 C-NMR were obtained with complete proton decoupling. MS and HRMS data were recorded in a VG Micromass ZAB-2F spectrometer and an ESI instrument LCT Premier XE Micromass (ESI-TOF). IR spectra were recorded on a Bruker IFS 28/55 spectrophotometer. All compounds were named using the ACD40 Name-Pro program, which is based on IUPAC rules.
General Procedures for the Synthesis of 4-Substituted 1,2,3-Triazolyl-Naphthoquinonic Derivatives
Method A: A solution of 0.57 mmol of the corresponding azide and 121.9 mg (0.57 mmol) of the alkyne in 6 mL of CH 2 Cl 2 (DCM) was added to a mixture of CuSO 4 . 5H 2 O (5.7 mg, 0.023 mmol) and sodium ascorbate (13.7 mg, 0.069 mmol) in 6 mL of water. The reaction mixture was stirred vigorously at room temperature until the disappearance of the alkyne. Then it was extracted with DCM (3 × 15 mL) and purified through silica gel column chromatography with a growing gradient of polarity DCM:MeOH (100:0-0:100). Method B: The alkyne and 1.0 equivalent of the corresponding azide were dissolved in 5 mL of dried CH 3 CN. Then, CuI (15-25 mol %) was added and the reaction mixture was stirred under argon atmosphere and at room temperature for 72 h. The solvent was removed under reduced pressure and purified through silica gel column chromatography with a growing gradient of polarity DCM:MeOH (100:0-0:100) when needed.
Method C: A solution of the corresponding boronic acid (0.24 mmol) and 78.5 mg (1.2 mmol) of sodium azide in 1.5 mL of H 2 O were added to a vigorously stirred mixture of Cu 2 O (3.4 mg, 0.024 mmol) in 0.06 mL of 20% of NH 3 and 0.12 mL of H 2 O. The reaction mixture was stirred for 16 h at room temperature under an oxygen atmosphere. Then, 30 mg (0.14 mmol) of N-propargylated naphthoquinone (6), 8.11 mg (0.041 mmol) of sodium ascorbate, 1.5 mL of H 2 O, and 3 mL of acetone were added. After stirring for 48 h, the reaction mixture was extracted with ethyl acetate (EtOAc). Subsequently, the aqueous phase was acidified with 5% HCl until pH 2 and it was extracted with EtOAc (3 × 15 mL). The combined organic phases were dried over anhydrous MgSO 4 and, after the elimination of the solvent, the corresponding residue was purified by silica gel column cromatography (CC) or TLC-preparative with DCM or 5% DCM/MeOH. 
2-[(1-Bencyl-triazol-4-yl)methoxy]-naphthalene-1,4-dione (3c)
Following the experimental procedure described in method A, from 76.5 mg (0.57 mmol) of 1-azidomethylbenzene 2c and 121.9 mg (0.57 mmol) of the alkyne, we synthesized compound 3c (169.4 mg, 85%). 
2-[(1-Phenyltriazol-4-yl)methoxy]-naphthalene-1,4-dione (3j)
Following the general procedure described in method B, 52.7 mg (0.25 mmol) of the alkyne and 25 mol % of CuI were stirred at room temperature for 72 h. Then, the solvent was removed at reduced pressure and the solid was washed with n-hexane, yielding triazole 3j (24.8 mg, 30%) without further purification. 1 (12); 274 (10); 173 (8); 146 (7) ; 130 (100); 89 (11); 77 (37); 57 (9); HREIMS: 331.0954 (calcd for C 19 H 13 N 3 O 3 331.0957); FT-IR (ATR) ν max : 3137, 2923, 1679, 1643, 1600, 1504, 1258, 1232, 1038, 1007, 865 cm −1 .
2-[(1-(2-Methoxyphenyl)-triazol-4-yl)methoxy]-naphthalene-1,4-dione (3k)
Following the general procedure described in method B, 53.9 mg (0.25 mmol) of the alkyne, 37.8 mg (0.25 mmol) of 2-methoxybenzylazide, and 25 mol % of CuI were stirred at room temperature for 72 h. Then, the solvent was removed at reduced pressure and the solid was washed with n-hexane, yielding triazole 3k (80.3 mg, 88%) without further purification. Following the general procedure described in method B, 52.9 mg (0.25 mmol) of the alkyne, 37.3 mg (0.25 mmol) of 3-methoxybenzylazide, and 25% mol of CuI were stirred at room temperature for 72 h. Then, the solvent was removed at reduced pressure and the solid was washed with n-hexane, yielding triazole 3l (84.6 mg, 94%) without further purification. 1 
2-[(1-(4-Methoxyphenyl)-triazol-4-yl)methoxy]-naphthalene-1,4-dione (3o)
Following the general procedure described in method B, 44.8 mg (0.21 mmol) of the alkyne, 31.4 mg (0.21 mmol) of 4-methoxybenzylazide, and 25% mol of CuI were stirred at room temperature for 72 h. Then, the solvent was removed at reduced pressure and the solid was washed with n-hexane, ring. The nature of the substituents on the aromatic ring seemed to modulate the antiplasmodial activity. The results obtained from docking studies supported the hypothesis that the enzyme Pf DHODH might be the target of these compounds in the parasite. The most active compounds (3d, 3f, 3j, 3l, 3m, and 3s) showed values for physicochemical descriptors within the accepted ranges for drug-like molecules. All these results suggest that these compounds could serve as promising lead compounds for further research.
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